$0.77
+0.02 (+2.68%)
USD · as of 2026-08-27 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MIRA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 2 tracked-famous managers (CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.5 days to cover (settled 2026-08-14) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetics of Oral Ketamir-2 in Healthy Adult SubjectsNCT07791303Number of Participants with Incidence of adverse eventsQuadruple-masked · Treatment | Phase 1 | Completed | Drug: Ketamir-2, Placebo | Healthy Adult Participants | 57 | 2026-03-05actual | 2026-08-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-27